Overview

Efficacy and Tolerance of Peg-interferon Alpha 2a Added to Tenofovir and Emtricitabine in AgHBe Positive HBV-HIV Co-infected Patients

Status:
Completed

Trial end date:
2012-10-01

Target enrollment:

Participant gender:

Summary

HBe seroconversion is an important goal for anti-HBV treatment, since it is associated with a non progressive liver infection and a better clinical outcome. However, the rate of HBe seroconversion is low in HIV-HBV co-infected patients, mostly treated by tenofovir and emtricitabine. This study will evaluate the efficacy and the safety of a one-year Peg-interferon alpha 2a additional treatment in patients already treated by tenofovir and emtricitabine without reaching HBe seroconversion.

Phase:

Phase 2/Phase 3

Details

Lead Sponsor:

French National Agency for Research on AIDS and Viral Hepatitis

Collaborators:

Gilead Sciences
Roche Pharma AG

Treatments:

Emtricitabine
Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination
Interferon-alpha
Interferons
Peginterferon alfa-2a
Tenofovir